In his first public remarks since a false tweet inflamed outrage over the cost of insulin in the US, Eli Lilly CEO David Ricks defended his company's pricing—but also conceded it could be lower.
"It probably highlights that we have more work to do to bring down the cost of insulin for more people,” Ricks said of the Twitter fury.
Follow
@Valdis https://youtu.be/jn4HvRkBbfk
This work by @ExtraCreditz (Twitter) is a very simplified telling of insulin's development. It also explains why it was never intended to be Eli Lilly's cash cow putting people in hoc for this medication.
